Last reviewed · How we verify
Fluoxetine + Valsartan
This combination pairs a selective serotonin reuptake inhibitor with an angiotensin II receptor blocker to address both mood and blood pressure regulation.
This combination pairs a selective serotonin reuptake inhibitor with an angiotensin II receptor blocker to address both mood and blood pressure regulation. Used for Depression with concurrent hypertension, Anxiety disorders with hypertension.
At a glance
| Generic name | Fluoxetine + Valsartan |
|---|---|
| Also known as | Prozac, Diovan |
| Sponsor | National Cheng-Kung University Hospital |
| Drug class | SSRI + ARB combination |
| Target | Serotonin transporter (SERT) and Angiotensin II type 1 receptor (AT1R) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fluoxetine inhibits serotonin reuptake in the central nervous system, treating depression and anxiety disorders. Valsartan blocks angiotensin II type 1 receptors in vascular smooth muscle and the adrenal gland, reducing blood pressure and providing cardiovascular protection. The combination addresses comorbid depression and hypertension in a single regimen.
Approved indications
- Depression with concurrent hypertension
- Anxiety disorders with hypertension
Common side effects
- Nausea
- Dizziness
- Headache
- Hyperkalemia
- Diarrhea
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluoxetine + Valsartan CI brief — competitive landscape report
- Fluoxetine + Valsartan updates RSS · CI watch RSS
- National Cheng-Kung University Hospital portfolio CI